Abstract
ObjectivesEfficacy and safety of erenumab, a human anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, were evaluated in patients with episodic migraine (EM) in a phase 3 trial (NCT02483585).MethodsFive-hundred and seventy...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have